MSFT 417.83 -0.6798% AAPL 226.85 0.2829% NVDA 118.714 1.465% GOOGL 165.686 -0.7809% GOOG 167.125 -0.7689% AMZN 185.38 0.135% META 573.28 -0.5534% AVGO 171.45 2.3765% TSLA 249.36 -3.3563% TSM 175.7 2.1096% LLY 890.255 0.6529% V 276.22 -0.4971% JPM 207.51 0.227% UNH 592.97 1.6578% NVO 116.255 -1.4872% WMT 80.19 -1.3289% LVMUY 147.83 0.2441% XOM 120.8281 0.7489% LVMHF 740.0 0.955% MA 495.19 -0.2397%
Last update at 2024-10-02T18:49:00Z
Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
Mon 30 Sep 24, 04:40 PMGrant of Restricted Stock Units and Warrants to Employees in Genmab
Thu 26 Sep 24, 07:17 PMGenmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers
Fri 30 Aug 24, 09:49 PMTop High Growth Tech Stocks To Watch In August 2024
Wed 28 Aug 24, 12:05 PMGenmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Mon 26 Aug 24, 04:26 PMAbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
Tue 20 Aug 24, 01:44 PMGenmab Announces Changes to its Executive Committee
Fri 16 Aug 24, 01:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7035.00M | 3983.00M | 5904.00M | 2859.00M | 1611.97M |
| Minority interest | - | - | - | 0.00000M | 0.00000M |
| Net income | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.14M |
| Selling general administrative | 2676.00M | 1283.00M | 661.00M | 342.00M | 213.69M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 14595.00M | 8482.00M | 10111.00M | 5366.00M | 3025.14M |
| Reconciled depreciation | 362.00M | 248.00M | 259.00M | 139.00M | 87.60M |
| Ebit | 6357.00M | 3018.00M | 6313.00M | 2638.00M | 1612.39M |
| Ebitda | 7043.00M | 3463.00M | 6756.00M | 2897.00M | 1699.98M |
| Depreciation and amortization | 686.00M | 445.00M | 443.00M | 259.00M | 87.60M |
| Non operating income net other | - | - | - | 0.00000M | 0.00000M |
| Operating income | 6357.00M | 3018.00M | 6313.00M | 2638.00M | 1380.28M |
| Other operating expenses | 8238.00M | 5464.00M | 3798.00M | 2728.00M | 1644.85M |
| Interest expense | 21.00M | 13.00M | 10.00M | 7.00M | 0.42M |
| Tax provision | 1513.00M | 975.00M | 1146.00M | 693.00M | 139.83M |
| Interest income | 324.00M | 197.00M | 184.00M | 348.00M | 62.92M |
| Net interest income | 303.00M | 184.00M | 174.00M | 334.00M | 62.51M |
| Extraordinary items | - | - | - | 0.00000M | 0.00000M |
| Non recurring | - | - | - | 0.00000M | 0.00000M |
| Other items | - | - | - | 0.00000M | 0.00000M |
| Income tax expense | 1513.00M | 975.00M | 1146.00M | 693.00M | 139.83M |
| Total revenue | 14595.00M | 8482.00M | 10111.00M | 5366.00M | 3025.14M |
| Total operating expenses | 8238.00M | 5464.00M | 3798.00M | 2728.00M | 1644.85M |
| Cost of revenue | - | - | - | 0.00000M | 0.00000M |
| Total other income expense net | 678.00M | 965.00M | -409.00000M | 221.00M | 231.69M |
| Discontinued operations | - | - | - | 0.00000M | 0.00000M |
| Net income from continuing ops | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.14M |
| Net income applicable to common shares | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.00M |
| Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 35289.00M | 30278.00M | 24627.00M | 21143.00M | 15144.00M |
| Intangible assets | 101.00M | 146.00M | 254.00M | 338.00M | 470.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | - | - | 10398.00M |
| Total liab | 3679.00M | 2837.00M | 2431.00M | 2022.00M | 1096.00M |
| Total stockholder equity | 31610.00M | 27441.00M | 22196.00M | 19121.00M | 14048.00M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 54.00M | 1716.00M | 1130.00M | 1185.00M | 912.00M |
| Common stock | 66.00M | 66.00M | 66.00M | 66.00M | 65.00M |
| Capital stock | 66.00M | 66.00M | 66.00M | 66.00M | 65.00M |
| Retained earnings | 19023.00M | 14968.00M | 10020.00M | 7107.00M | 2130.00M |
| Other liab | - | 491.00M | 500.00M | 492.00M | 3.00M |
| Good will | - | - | - | - | 0.00000M |
| Other assets | - | 300.00M | 291.00M | 197.00M | 150.00M |
| Cash | 14867.00M | 9893.00M | 8957.00M | 7260.00M | 3552.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2484.00M | 1823.00M | 1568.00M | 1253.00M | 938.00M |
| Current deferred revenue | 33.00M | 33.00M | 26.00M | 26.00M | - |
| Net debt | -14097.00000M | -9296.00000M | -8532.00000M | -6941.00000M | -3371.00000M |
| Short term debt | 90.00M | 74.00M | 62.00M | 42.00M | 26.00M |
| Short long term debt | - | - | - | - | 0.00000M |
| Short long term debt total | 770.00M | 597.00M | 425.00M | 319.00M | 181.00M |
| Other stockholder equity | 12461.00M | 12309.00M | 12029.00M | 11894.00M | 11755.00M |
| Property plant equipment | - | 1322.00M | 975.00M | 736.00M | 414.00M |
| Total current assets | 33139.00M | 28377.00M | 22736.00M | 18791.00M | 13961.00M |
| Long term investments | 134.00M | 133.00M | 371.00M | 1081.00M | 149.00M |
| Net tangible assets | - | 27295.00M | 21942.00M | 18783.00M | 13578.00M |
| Short term investments | 13268.00M | 12431.00M | 10381.00M | 8819.00M | 7419.00M |
| Net receivables | 4947.00M | 6053.00M | 3398.00M | 2712.00M | 2990.00M |
| Long term debt | - | - | - | - | 0.00000M |
| Inventory | 57.00M | - | - | - | -10398.00000M |
| Accounts payable | 2307.00M | - | 350.00M | - | 0.00000M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | 60.00M | 98.00M | 81.00M | 54.00M | 98.00M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | 66.00M | 65.00M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | - | 48.00M | 27.00M | 20.00M | 11.00M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 2150.00M | 1901.00M | 1891.00M | 2352.00M | 1183.00M |
| Capital lease obligations | 770.00M | 597.00M | 425.00M | 319.00M | 181.00M |
| Long term debt total | - | - | - | - | 155.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2761.00000M | -709.00000M | -2351.00000M | -1983.00000M | -1777.55300M |
| Change to liabilities | 283.00M | 304.00M | 681.00M | 440.00M | 134.00M |
| Total cashflows from investing activities | -2761.00000M | -961.00000M | -2351.00000M | -1983.00000M | -1778.00000M |
| Net borrowings | -73.00000M | -58.00000M | -44.00000M | -31.00000M | -31.00000M |
| Total cash from financing activities | -789.00000M | -420.00000M | 71.00M | 3660.00M | -70.90100M |
| Change to operating activities | - | -770.00000M | -770.00000M | -770.00000M | -770.00000M |
| Net income | 7035.00M | 3983.00M | 5904.00M | 2859.00M | 1611.97M |
| Change in cash | 936.00M | 1697.00M | 3708.00M | 3019.00M | -814.63800M |
| Begin period cash flow | 8957.00M | 7260.00M | 3552.00M | 533.00M | 1347.55M |
| End period cash flow | 9893.00M | 8957.00M | 7260.00M | 3552.00M | 532.91M |
| Total cash from operating activities | 3912.00M | 2228.00M | 6433.00M | 1326.00M | 1014.79M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 3873.00M | 0.31M |
| Depreciation | 362.00M | 248.00M | 259.00M | 139.00M | 87.60M |
| Other cashflows from investing activities | - | - | - | -1872.00000M | -1300.18700M |
| Dividends paid | - | - | - | 0.00000M | 0.00000M |
| Change to inventory | - | - | - | 0.00000M | 0.00000M |
| Change to account receivables | -2213.00000M | -1074.00000M | 306.00M | -0.00006M | -0.00004M |
| Sale purchase of stock | -908.00000M | -447.00000M | 0.00000M | 0.00000M | -146.17500M |
| Other cashflows from financing activities | 192.00M | 85.00M | 115.00M | -182.00000M | 74.96M |
| Change to netincome | -78.00000M | -314.00000M | 422.00M | 211.00M | 89.00M |
| Capital expenditures | 317.00M | 252.00M | 307.00M | 111.00M | 477.37M |
| Change receivables | - | - | - | 0.00000M | 0.00000M |
| Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
| Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
| Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
| Change in working capital | -1930.00000M | -770.00000M | 987.00M | -1218.00000M | -634.37200M |
| Stock based compensation | 439.00M | 310.00M | 200.00M | 147.00M | 90.76M |
| Other non cash items | -1994.00000M | -997.00000M | 409.00M | -216.00000M | -231.68800M |
| Free cash flow | 3595.00M | 1976.00M | 6126.00M | 1215.00M | 537.42M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GMAB Genmab AS |
-0.5 2.07% | 23.65 | 23.34 | 26.04 | 1.17 | 4.18 | 0.94 | 2.58 |
| NVO Novo Nordisk A/S |
-1.755 1.49% | 116.25 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.06 1.74% | 116.20 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-7.275 1.55% | 462.49 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.415 0.42% | 1042.49 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
| Name | Title | Year Born |
|---|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, Pres & CEO | 1961 |
| Mr. Anthony Pagano | Exec. VP & CFO | 1978 |
| Mr. Anthony Mancini | Exec. VP & COO | 1971 |
| Dr. Judith V. Klimovsky M.D. | Exec. VP & Chief Devel. Officer | 1958 |
| Dr. Tahamtan Ahmadi | Exec. VP, Chief Medical Officer & Head of Experimental Medicines | 1973 |
| Dr. Mijke Zachariasse Ph.D. | Director of Protein Production & Chemist and Non-Independent Director | 1974 |
| Dr. Rima Bawarshi Nassar Ph.D. | VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director | 1953 |
| Mr. Peter Ros | Sr. Director of Fin. & Accounting | NA |
| Mr. Andrew Carlsen | Sr. Director, VP & Head of Investor Relations | NA |
| Ms. Birgitte Stephensen M.Sc. | Exec. VP & Chief Legal Officer | 1961 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...